 | Up a level |
Journal Article
Harrison, Claire, Andreasson, Bjorn, Cambier, Nathalie, Gerds, Aaron, Grosicki, Sebastian, Illes, Arpad, Kiladjian, Jean-Jacques, Lavie, David, Mesa, Ruben, Palmer, Jeanne, Passamonti, Francesco, Perkins, Andrew, Sacha, Tomasz, Scheid, Christof, Todorieva-Todorova, Doroteya, Vannucchi, Alessandro, Wozny, Tomasz, Klencke, Barbara, Kowalski, Mark and Verstovsek, Srdan (2020). Long-Term Safety of Momelotinib in JAK Inhibitor-Naive and Previously JAK Inhibitor-Treated Intermediate-/High-Risk Myelofibrosis Patients. Clin. Lymphoma Myeloma Leuk., 20. S. S330 - 2. DALLAS: CIG MEDIA GROUP, LP. ISSN 2152-2669
Verstovsek, Srdan, Chen, Chih-Cheng, Egyed, Miklos, Ellis, Martin, Fox, Laura, Goh, Yeow T., Gupta, Vikas 
ORCID: 0000-0002-1419-8607, Harrison, Claire, Kiladjian, Jean-Jacques ORCID: 0000-0002-8121-438X, Lazaroiu, Mihaela C., Mead, Adam, McLornan, Donal, McMullin, Mary F., Oh, Stephen T., Perkins, Andrew, Platzbecker, Uwe, Scheid, Christof, Vannucchi, Alessandro, Yoon, Sung-Soo, Kowalski, Mark M. and Mesa, Ruben A.
(2021).
MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.
Future Oncol., 17 (12).
S. 1449 - 1459.
LONDON:
FUTURE MEDICINE LTD.
ISSN 1744-8301